4.7 Article

Serum 25-Hydroxyvitamin D, Calcium Intake, and Risk of Type 2 Diabetes After 5 Years Results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study)

期刊

DIABETES CARE
卷 34, 期 5, 页码 1133-1138

出版社

AMER DIABETES ASSOC
DOI: 10.2337/dc10-2167

关键词

-

资金

  1. National Health and Medical Research Council (NHMRC) [233200]
  2. Australian Government Department of Health and Ageing
  3. Abbott Australasia Pty. Ltd.
  4. Alphapharm Pty. Ltd.
  5. AstraZeneca
  6. BristolMyers Squibb
  7. City Health Centre-Diabetes Service-Canberra
  8. Department of Health and Community Services-Northem Territory
  9. Department of Health and Human Services Tasmania
  10. Department of Health New South Wales
  11. Department of Health Western Australia
  12. Department of Health South Australia
  13. Department of Human Services Victoria
  14. Diabetes Australia
  15. Diabetes Australia Northern Territory
  16. Eli Lilly Australia
  17. Estate of the Late Edward Wilson
  18. GlaxoSmithKline
  19. Jack Brockhoff Foundation
  20. Janssen-Cilag
  21. Kidney Health Australia
  22. Marian FH Flack Trust
  23. Menzies Research Institute
  24. Merck Sharp Dohme
  25. Novartis Pharmaceuticals
  26. Novo Nordisk Pharmaceuticals
  27. Pfizer Pty. Ltd.
  28. Pratt Foundation
  29. Queensland Health
  30. Roche Diagnostics Australia
  31. Royal Prince Alfred Hospital, Sydney
  32. sanofi-aventis
  33. Sanofi Synthelabo
  34. NHMRC [425849]
  35. Victorian Health Promotion Foundation
  36. Laval University, Quebec, Canada

向作者/读者索取更多资源

OBJECTIVE-To examine whether serum 25-hydroxyvitamin D (25OHD) and dietary calcium predict incident type 2 diabetes and insulin sensitivity. RESEARCH DESIGN AND METHODS-A total of 6,537 of the 11,247 adults evaluated in 1999-2000 in the Australian Diabetes, Obesity and Lifestyle (AusDiab) study, returned for oral glucose tolerance test (OGTT) in 2004-2005. We studied those without diabetes who had complete data at baseline (n = 5,200; mean age 51 years; 55% were women; 92% were Europids). Serum 25OHD and energy-adjusted calcium intake (food frequency questionnaire) were assessed at baseline. Logistic regression was used to evaluate associations between serum 25OHD and dietary calcium on 5-year incidence of diabetes (diagnosed by OGTT) and insulin sensitivity (homeostasis model assessment of insulin sensitivity [HOMA-S]), adjusted for multiple potential confounders, including fasting plasma glucose (FPG). RESULTS-During the 5-year follow-up, 199 incident cases of diabetes were diagnosed. Those who developed diabetes had lower serum 25OHD (mean 58 vs. 65 nmol/L; P < 0.001) and calcium intake (mean 881 vs. 923 mg/day; P = 0.03) compared with those who remained free of diabetes. Each 25 nmol/L increment in serum 25OHD was associated with a 24% reduced risk of diabetes (odds ratio 0.76 [95% CI 0.63-0.92]) after adjusting for age, waist circumference, ethnicity, season, latitude, smoking, physical activity, family history of diabetes, dietary magnesium, hypertension, serum triglycerides, and FPG. Dietary calcium intake was not associated with reduced diabetes risk. Only serum 25OHD was positively and independently associated with HOMA-S at 5 years. CONCLUSIONS-Higher serum 25OHD levels, but not higher dietary calcium, were associated with a significantly reduced risk of diabetes in Australian adult men and women.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据